This company has shut down. Kantum Pharma is no longer operating — its last tracked round was a Series A in 2021.
Explore the Startup GraveyardKantum Pharma is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI.
Kantum Pharma has raised $3.5M in total funding. The most recent round was Series A. The last funding was announced in July 2021.
Kantum Pharma's investors include Broadview Ventures, Sidecar Angels, 10X Venture Partners.
Kantum Pharma is headquartered in Concord, United States.
Kantum Pharma is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI.
Kantum Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kantum Pharma — Funding & Investors." VCBacked, July 12, 2021, https://www.vcbacked.co/company/kantum-pharma. Accessed August 13, 2026.
VCBacked. (2021). Kantum Pharma — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/kantum-pharma
{{cite web |title=Kantum Pharma — Funding & Investors |url=https://www.vcbacked.co/company/kantum-pharma |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated